Lichtenberger Ramtin, Maul Lara Valeska, Birkenmaier Ion, Oyanguren Iker, Ak Melike, Heidemeyer Kristine, Schlapbach Christoph, Yawalkar Nikhil, Egeberg Alexander, Thomsen Simon Francis, Thyssen Jacob P, Sorbe Christina, Boehncke Wolf-Henning, Conrad Curdin, Cozzio Antonio, Kokolakis Georgios, Micheroli Raphael, Wu Jashin J, Kündig Thomas, Navarini Alexander, Maul Julia-Tatjana
Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland; Life Science Zurich Graduate School, Faculty of Science, University of Zurich, Zurich, Switzerland.
Acta Derm Venereol. 2025 Feb 6;105:adv42296. doi: 10.2340/actadv.v105.42296.
Real-world data on gender differences in quality of life among psoriasis patients before and during treatment are scarce. This study analysed data of 748 adults with moderate-to-severe psoriasis enrolled in the Swiss Dermatology Network of Targeted Therapy registry between 2011 and 2023. Quality of life was assessed using the Dermatological Life Quality Index at baseline and at 3, 6, 12, 18, and 24 months. At baseline, women reported significantly lower quality of life than men, with higher Dermatological Life Quality Index scores in the IL-17 inhibitor group (15.0 vs 11.0, p = 0.027), IL-12/23 inhibitor group (7.5 vs 7.0, p = 0.049), and non-biologic therapy group (13.0 vs 9.0, p < 0.001). Although quality of life improved across all subgroups during the follow-up period, women treated with IL-12/23 inhibitors continued to report worse quality of life compared with men after 2 years (p < 0.05), while no significant differences were observed with other therapies. These findings emphasize that women with psoriasis experience lower quality of life at treatment initiation and throughout non-biologic and biologic therapies, underlining the importance of addressing gender-specific differences in the management of psoriasis.
关于银屑病患者治疗前和治疗期间生活质量性别差异的真实世界数据很少。本研究分析了2011年至2023年期间纳入瑞士靶向治疗登记皮肤科网络的748例中重度银屑病成人患者的数据。在基线以及3、6、12、18和24个月时使用皮肤病生活质量指数评估生活质量。在基线时，女性报告的生活质量显著低于男性，在白细胞介素-17抑制剂组（15.0对11.0，p = 0.027）、白细胞介素-12/23抑制剂组（7.5对7.0，p = 0.049）和非生物治疗组（13.0对9.0，p < 0.001）中皮肤病生活质量指数得分更高。尽管在随访期间所有亚组的生活质量都有所改善，但与男性相比，接受白细胞介素-12/23抑制剂治疗的女性在2年后报告的生活质量仍然较差（p < 0.05），而其他治疗未观察到显著差异。这些发现强调，银屑病女性在治疗开始时以及整个非生物和生物治疗过程中生活质量较低，突出了在银屑病管理中解决性别特异性差异的重要性。
